Search research articles
Contact Us
Filters
Showing results (71-80 of 98) with videos related to
Page
of 10
Sort By:
The Lancet. Oncology
|
September 22, 2012
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
Karim Fizazi, Howard I Scher, Arturo Molina, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada
|
May 15, 2013
Management of small cell carcinoma of the bladder: Consensus guidelines from the Canadian Association of Genitourinary Medical Oncologists (CAGMO)
Patricia Moretto, Lori Wood, Urban Emmenegger, et al.
The Lancet. Oncology
|
June 16, 2025
Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial
Neeraj Agarwal, Arun A Azad, Joan Carles, et al.
Clinical Genitourinary Cancer
|
March 4, 2017
Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma
Guillermo De Velasco, Wanling Xie, Frede Donskov, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada
|
November 27, 2023
High-dose chemotherapy with autologous stem-cell transplantation for relapsed metastatic germ cell tumors The Alberta experience
Hanbo Zhang, Nimira S Alimohamed, Naveen S Basappa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 15, 2009
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study
Daniel Y C Heng, Wanling Xie, Meredith M Regan, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada
|
March 16, 2016
Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015
Wassim Kassouf, Armen Aprikian, Peter Black, et al.
Clinical Genitourinary Cancer
|
May 7, 2019
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205
Sebastien J Hotte, Kim N Chi, Anthony M Joshua, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada
|
April 1, 2018
Improving patient journey and quality of care: Summary from the second Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting
Wassim Kassouf, Armen Aprikian, Fred Saad, et al.
European Urology
|
May 27, 2020
Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer
Cameron Herberts, Andrew J Murtha, Simon Fu, et al.
Page
of 10
Search research articles
Search
Showing results (71-80 of 98) with videos related to
Sort By:
Page
of 10
The Lancet. Oncology
|
September 22, 2012
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
Karim Fizazi, Howard I Scher, Arturo Molina, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada
|
May 15, 2013
Management of small cell carcinoma of the bladder: Consensus guidelines from the Canadian Association of Genitourinary Medical Oncologists (CAGMO)
Patricia Moretto, Lori Wood, Urban Emmenegger, et al.
The Lancet. Oncology
|
June 16, 2025
Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial
Neeraj Agarwal, Arun A Azad, Joan Carles, et al.
Clinical Genitourinary Cancer
|
March 4, 2017
Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma
Guillermo De Velasco, Wanling Xie, Frede Donskov, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada
|
November 27, 2023
High-dose chemotherapy with autologous stem-cell transplantation for relapsed metastatic germ cell tumors The Alberta experience
Hanbo Zhang, Nimira S Alimohamed, Naveen S Basappa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 15, 2009
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study
Daniel Y C Heng, Wanling Xie, Meredith M Regan, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada
|
March 16, 2016
Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015
Wassim Kassouf, Armen Aprikian, Peter Black, et al.
Clinical Genitourinary Cancer
|
May 7, 2019
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205
Sebastien J Hotte, Kim N Chi, Anthony M Joshua, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada
|
April 1, 2018
Improving patient journey and quality of care: Summary from the second Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting
Wassim Kassouf, Armen Aprikian, Fred Saad, et al.
European Urology
|
May 27, 2020
Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer
Cameron Herberts, Andrew J Murtha, Simon Fu, et al.
Page
of 10